Condition

Gastric Retention

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions5

Lead sponsors shown3

Clinical trials

3 shown

Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric RetentionNCT07156591 · 2025-09-15

NOT_YET_RECRUITING

Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryNCT06500143 · 2024-10-09

COMPLETED

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy AdultsNCT03711825 · 2018-09-10

COMPLETED

Common interventions

EsophagogastroduodenoscopyPROCEDURE1 Gastric ultrasoundDIAGNOSTIC_TEST1 Imaging Assessment (MRI)PROCEDURE1 Imaging Assessment (U/S)PROCEDURE1 LYN-057DRUG1

Leading sponsors

Ciusss de L'Est de l'Île de Montréal 1 Fudan University 1 Lyndra Inc. 1

Trial status mix

COMPLETED2

NOT_YET_RECRUITING1

Phase mix

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.